CI

At a glance

ClinicalIndex Comparison Record
Phase 1Active· 21 enrolled
Drug / intervention
RYZ101 Dose Level 1 +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05595460
NCT05595460Phase 1Active
CompareCT.gov

Phase 1b Single Arm, Open-label Trial of RYZ101 in Combination With Carboplatin + Etoposide + Atezolizumab in Subjects With Somatostatin Receptor Expressing (SSTR+) Extensive Stage Small Cell Lung Cancer (ES-SCLC)

RayzeBio, Inc.·interventional·Posted Oct 27, 2022·Updated Apr 13, 2026

In Brief

A Phase 1 clinical trial evaluating RYZ101 Dose Level 1, RYZ101 Dose Level 2, and 5 other interventions for SCLC,Extensive Stage. Active but no longer recruiting, targeting 21 participants across 13 sites in 2 countries.

Detailed Summary

This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSCLC,Extensive Stage
CountriesPuerto Rico, United States
Collaborators--

Timeline

Phase 1Active
20232024202520262027
First PostedOct 27, 2022
Enrollment StartOct 10, 2022
Primary CompletionJul 1, 2027
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 3.7 years agoPrimary completion in 12 months

Interventions

RYZ101 Dose Level 1drug

Dose Level 1

RYZ101 Dose Level 2drug

Dose Level 2

RYZ101 Dose Level 3drug

Dose Level 3

RYZ101 Dose Level -1drug

Dose Level -1

Atezolizumabdrug

Atezolizumab

Carboplatindrug

Carboplatin

Etoposidedrug

Etoposide